Femasys earnings release, August 14, 2026
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the
FemBloc® clinical and regulatory program toward U.S. approval --
ATLANTA, August 14, 2026 – Femasys Inc.
(NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.
Corporate Highlights from 2Q 2026 to date
“During the second quarter of 2026 and into the third quarter of 2026, we made meaningful progress strengthening our financial position, advancing our commercial strategy and expanding the reach of our innovative fertility solutions,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “The completion of our $30 million private placement and restoration of Nasdaq compliance provide a stronger foundation to execute our growth strategy. We also achieved important commercial milestones, including the launch of FemaSeed Complete at ACOG 2026 and initial commercial use, advancing our strategy to expand access to first-line fertility treatment in the OB/GYN office and potentially enable earlier intervention. With this financing in place, we are well positioned to execute our commercial strategy, complete the U.S. FemBloc clinical program and advance our portfolio toward key value-creating milestones for patients and shareholders.”
Financial Results for Six Months Ended June 30, 2026
Financial Results for Quarter Ended June 30, 2026
For more information, please refer to the Company’s Form 10-Q filed August 14, 2026, which can be accessed on the SEC website.
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
(continued)
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
FEMASYS INC.
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
About Femasys Inc.
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed®
Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.
Learn more at www.femasys.com, or follow us on
X,
Facebook and
LinkedIn.
Financial statements
Income Statement
Three Months Ended June 30, — (unaudited)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Sales | 331,827 | 409,268 | 756,716 | 750,532 | |
| Cost of sales (excluding depreciation expense) | 142,436 | 158,171 | 301,042 | 275,437 | |
| Operating expenses: | Research and development | 1,946,878 | 1,414,429 | 3,256,279 | 4,382,901 |
| Operating expenses: | Sales and marketing | 1,293,998 | 984,977 | 2,609,753 | 1,893,544 |
| Operating expenses: | General and administrative | 1,931,578 | 1,616,972 | 3,713,968 | 3,339,685 |
| Operating expenses: | Depreciation and amortization | 82,811 | 86,285 | 165,081 | 171,138 |
| Operating expenses: | Total operating expenses | 5,255,265 | 4,102,663 | 9,745,081 | 9,787,268 |
| Operating expenses: | Loss from operations | -5,065,874 | -3,851,566 | -9,289,407 | -9,312,173 |
| Other income (expense): | Interest income | 19,694 | 17,144 | 69,521 | 36,173 |
| Other income (expense): | Change in fair value of conversion option liability | 219,000 | 1,732,413 | ||
| Other income (expense): | Change in fair value of warrants liabilities | 545,000 | 4,228,000 | ||
| Other income (expense): | Interest expense | -186,050 | -491,500 | -362,657 | -950,949 |
| Other income (expense): | Other expense | -260,000 | -260,000 | ||
| Other income (expense): | Total other income (expense), net | 597,644 | -734,356 | 5,667,277 | -1,174,776 |
| Other income (expense): | Loss before income taxes | -4,468,230 | -4,585,922 | -3,622,130 | -10,486,949 |
| Other income (expense): | Income tax expense (benefit) | 865 | 865 | -4,188 | |
| Other income (expense): | Net loss | -4,469,095 | -4,585,922 | -3,622,995 | -10,482,761 |
| Other income (expense): | Net loss attributable to common stockholders | -4,469,095 | -4,585,922 | -3,622,995 | -10,482,761 |
| Other income (expense): | Basic and diluted loss per share | -1.33 | -3.18 | -1.08 | -7.76 |
| Other income (expense): | Weighted-average common shares outstanding, basic and diluted | 3,357,117 | 1,444,036 | 3,344,767 | 1,351,264 |
Balance Sheet
June 30, 2026 — (unaudited)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 1,443,502 | 9,266,353 |
| Current assets: | Accounts receivable, net | 151,049 | 616,600 |
| Current assets: | Inventory | 6,191,277 | 5,740,249 |
| Current assets: | Prepaid and other current assets | 546,085 | 833,133 |
| Current assets: | Total current assets | 8,331,913 | 16,456,335 |
| Property and equipment, at cost: | Leasehold improvements | 1,238,886 | 1,238,886 |
| Property and equipment, at cost: | Office equipment | 87,515 | 78,155 |
| Property and equipment, at cost: | Furniture and fixtures | 424,586 | 417,876 |
| Property and equipment, at cost: | Machinery and equipment | 3,121,131 | 3,065,713 |
| Property and equipment, at cost: | Construction in progress | 919,412 | 897,885 |
| Property and equipment, at cost: | 5,791,530 | 5,698,515 | |
| Property and equipment, at cost: | Less accumulated depreciation | -3,932,324 | -3,802,940 |
| Property and equipment, at cost: | Net property and equipment | 1,859,206 | 1,895,575 |
| Long-term assets: | Lease right-of-use assets, net | 1,064,346 | 1,297,121 |
| Long-term assets: | Intangible assets, net of accumulated amortization | 115,499 | 134,914 |
| Long-term assets: | Other long-term assets | 918,618 | 940,232 |
| Long-term assets: | Total long-term assets | 2,098,463 | 2,372,267 |
| Long-term assets: | Total assets | 12,289,582 | 20,724,177 |
Balance Sheet
Liabilities and Stockholders’ Equity — (unaudited)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current liabilities: | Accounts payable | 2,337,354 | 1,830,124 |
| Current liabilities: | Accrued expenses | 1,033,712 | 1,265,773 |
| Current liabilities: | Clinical holdback – current portion | 42,726 | 52,644 |
| Current liabilities: | Operating lease liabilities – current portion | 473,034 | 487,624 |
| Current liabilities: | Total current liabilities | 3,886,826 | 3,636,165 |
| Long-term liabilities: | Clinical holdback – long-term portion | 54,598 | 52,370 |
| Long-term liabilities: | Convertible notes payable, net | 3,521,226 | 3,178,864 |
| Long-term liabilities: | Conversion option liability | 2,014,000 | |
| Long-term liabilities: | Warrants liabilities | 4,943,000 | |
| Long-term liabilities: | Operating lease liabilities – long-term portion | 795,985 | 1,030,476 |
| Long-term liabilities: | Total long-term liabilities | 4,371,809 | 11,218,710 |
| Long-term liabilities: | Total liabilities | 8,258,635 | 14,854,875 |
| Stockholders’ equity: | Common stock, $0.001 par, 200,000,000 authorized, 3,029,829 shares issued and 3,023,967 outstanding as of June 30, 2026; and 2,986,116 shares issued and 2,980,254 outstanding as of December 31, 2025 | 3,030 | 2,986 |
| Stockholders’ equity: | Treasury stock, 5,862 common shares | -60,000 | -60,000 |
| Stockholders’ equity: | Warrants | 5,961,150 | 5,246,150 |
| Stockholders’ equity: | Additional paid-in capital | 147,575,906 | 146,506,310 |
| Stockholders’ equity: | Accumulated deficit | -149,449,139 | -145,826,144 |
| Stockholders’ equity: | Total stockholders’ equity | 4,030,947 | 5,869,302 |
| Stockholders’ equity: | Total liabilities and stockholders' equity | 12,289,582 | 20,724,177 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC.
Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
# # #
Contacts:
IR@femasys.com
Media@femasys.com